Biomea Fusion Inc (BMEA)

$1.72 -0.02 (-1.15%)
Market Cap 103.55M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 337,200
Avg Vol 1,373,026
Day's Range N/A - N/A
Shares Out 59.51M
Stochastic %K 81%
Beta -0.14
Analysts Strong Sell
Price Target $8.00

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
BobBijawklah
BobBijawklah Aug. 19 at 6:20 PM
$BMEA the problem is that the two cofounders gifted themselves millions and millions of shares and to get icovamenib they gift millions of shaers all at 0 dollars. But the drug works if and when they can get a trial design accepted for SIDD. Honestly i still think they could file for all t2d as the drug is safe and the duration of treatment is logner. IF the fda would accept endpoints like cpeptide and meal fasting insulin levels.
1 · Reply
BobBijawklah
BobBijawklah Aug. 19 at 5:51 PM
$VKTX its probably going to be similar to semaglutide for dropout rate. 50% by year one. So short term does it work yes . but i think their is a gem everyone is missing $BMEA https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-reports-new-preclinical-data-icovamenib . Adding icovamenib to semaglutide saw a 11.5% body weight decrease over 13 weeks on top of the semaglutide %. And a fat mass drop of 29%. Meaning fat replaced by muscle. And it naturally restores your bodies ability to regulate its own insulin without any artificial hormones essentially allowing you to controll your blood sugar and weight for many years without taking another pill or shot. Look at the data look at the science it restores beta cells ask yourself what do beta cells do. 10x plus current price easy when the dust settles on their trials. Is viking going to get approved probably but Icovamenib has a low single digit drop out if that.
0 · Reply
raulsan79trader
raulsan79trader Aug. 19 at 8:13 AM
$BMEA has been holding steady around $1.74, showing a 6% gain over the past week. Momentum is cautiously positive, with resistance seen in the $1.75–$1.80 range - Analyst sentiment remains bullish despite trimmed targets, with average price expectations well above current levels. Recent clinical data from the COVALENT-111 trial continues to support the company’s diabetes program, while early-stage oncology work seeks partners - In the short term, watch for a breakout above $1.80 on strong volume to signal renewed strength. A dip below $1.69 would risk returning to bearish consolidation
0 · Reply
GODOFUSD
GODOFUSD Aug. 18 at 9:36 PM
$BMEA buyers everywhere 📈🚀 https://whalewisdom.com/stock/bmea
0 · Reply
hashbridges
hashbridges Aug. 18 at 8:04 PM
$BMEA H. C. Wainwright downgrade is practically a badge of honor. They must have gotten turned down for the offering underwriting in the Summer - which shows good judgment by the Board.
0 · Reply
GODOFUSD
GODOFUSD Aug. 18 at 6:55 PM
$BMEA Until 1.65 HOLD we are fine. I have the feeling that this time we SR flip 200EMA
0 · Reply
Quantis
Quantis Aug. 18 at 3:54 PM
$LGVN: Roth Capital cuts target to $3 from $10, citing dilution and Q2 results. From biotech hope to biotech nope. $BMEA: H.C. Wainwright slashes target to $4 from $18, maintaining a Buy rating. Dilution concerns overshadow diabetes and obesity programs. $LODE: Analysts slash outlook to $4 as dilution reigns supreme. More shares, less value… and the moon keeps moving further away. $CELC: Needham lowers target to $70 from $74, citing dilution concerns. Oncology dreams diluted by capital raises. $LULU: JPMorgan downgrades to Neutral with a $224 target, citing high valuation and slowing growth. Athleisure dreams on a treadmill.
0 · Reply
sirspanky
sirspanky Aug. 18 at 2:44 PM
$HCTI ⏳ countdown → Aug 28th = compliance milestone 🚨 After the Aug 1st split, the 20 trading day clock runs out on the 28th — that’s when the company can finally check the box on Nasdaq compliance ✅. 📊 Pair that with: Strong Q2 earnings turnaround 📈 Acquisitions bringing in contracts 💼 Institutional filings showing confidence 💪 28th becomes the perfect launchpad for management to start dropping PRs + updates to fuel momentum. This isn’t just another ticker — it’s a turnaround story aligning with compliance & catalysts. Tagging: $PLTR $BMEA
3 · Reply
Rob88ynn
Rob88ynn Aug. 17 at 4:22 PM
$BMEA https://www.ainvest.com/news/blue-owl-capital-holdings-lp-acquires-3-800-000-shares-biomea-fusion-strategic-investment-biotechnology-sector-2508/
0 · Reply
GODOFUSD
GODOFUSD Aug. 15 at 3:59 PM
$BMEA this stock will soon gap up into the moon
0 · Reply
Latest News on BMEA
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 5, 2025, 4:05 PM EDT - 14 days ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jul 24, 2025, 7:00 AM EDT - 26 days ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 7:00 AM EDT - 2 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 18, 2025, 6:28 AM EDT - 2 months ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Biomea Fusion Announces Pricing of Public Offering of Securities

Jun 17, 2025, 11:15 PM EDT - 2 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 2 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

Biomea Fusion Announces Proposed Public Offering of Securities

Jun 17, 2025, 4:33 PM EDT - 2 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Jun 13, 2025, 6:45 AM EDT - 2 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 14, 2025, 4:05 PM EDT - 3 months ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025, 4:05 PM EDT - 3 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 4:01 PM EDT - 5 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:10 PM EDT - 5 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 5 months ago

Biomea Fusion Announces Leadership Transition

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 24, 2025, 8:30 AM EDT - 5 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 8:00 AM EST - 6 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 27, 2025, 8:00 AM EST - 6 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 10:41 AM EST - 8 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:10 AM EST - 8 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 16, 2024, 6:15 PM EST - 8 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 12, 2024, 5:02 PM EST - 8 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Dec 9, 2024, 4:01 PM EST - 9 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 6, 2024, 8:00 AM EST - 9 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 10 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 10 months ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 30, 2024, 4:00 PM EDT - 10 months ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 4:46 PM EDT - 10 months ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 10 months ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Oct 28, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 10 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Oct 22, 2024, 11:00 AM EDT - 10 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Oct 21, 2024, 9:00 AM EDT - 10 months ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 10 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 19, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 18, 2024, 11:00 AM EDT - 10 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Oct 15, 2024, 4:05 PM EDT - 11 months ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Oct 8, 2024, 11:00 AM EDT - 11 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

BobBijawklah
BobBijawklah Aug. 19 at 6:20 PM
$BMEA the problem is that the two cofounders gifted themselves millions and millions of shares and to get icovamenib they gift millions of shaers all at 0 dollars. But the drug works if and when they can get a trial design accepted for SIDD. Honestly i still think they could file for all t2d as the drug is safe and the duration of treatment is logner. IF the fda would accept endpoints like cpeptide and meal fasting insulin levels.
1 · Reply
BobBijawklah
BobBijawklah Aug. 19 at 5:51 PM
$VKTX its probably going to be similar to semaglutide for dropout rate. 50% by year one. So short term does it work yes . but i think their is a gem everyone is missing $BMEA https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-reports-new-preclinical-data-icovamenib . Adding icovamenib to semaglutide saw a 11.5% body weight decrease over 13 weeks on top of the semaglutide %. And a fat mass drop of 29%. Meaning fat replaced by muscle. And it naturally restores your bodies ability to regulate its own insulin without any artificial hormones essentially allowing you to controll your blood sugar and weight for many years without taking another pill or shot. Look at the data look at the science it restores beta cells ask yourself what do beta cells do. 10x plus current price easy when the dust settles on their trials. Is viking going to get approved probably but Icovamenib has a low single digit drop out if that.
0 · Reply
raulsan79trader
raulsan79trader Aug. 19 at 8:13 AM
$BMEA has been holding steady around $1.74, showing a 6% gain over the past week. Momentum is cautiously positive, with resistance seen in the $1.75–$1.80 range - Analyst sentiment remains bullish despite trimmed targets, with average price expectations well above current levels. Recent clinical data from the COVALENT-111 trial continues to support the company’s diabetes program, while early-stage oncology work seeks partners - In the short term, watch for a breakout above $1.80 on strong volume to signal renewed strength. A dip below $1.69 would risk returning to bearish consolidation
0 · Reply
GODOFUSD
GODOFUSD Aug. 18 at 9:36 PM
$BMEA buyers everywhere 📈🚀 https://whalewisdom.com/stock/bmea
0 · Reply
hashbridges
hashbridges Aug. 18 at 8:04 PM
$BMEA H. C. Wainwright downgrade is practically a badge of honor. They must have gotten turned down for the offering underwriting in the Summer - which shows good judgment by the Board.
0 · Reply
GODOFUSD
GODOFUSD Aug. 18 at 6:55 PM
$BMEA Until 1.65 HOLD we are fine. I have the feeling that this time we SR flip 200EMA
0 · Reply
Quantis
Quantis Aug. 18 at 3:54 PM
$LGVN: Roth Capital cuts target to $3 from $10, citing dilution and Q2 results. From biotech hope to biotech nope. $BMEA: H.C. Wainwright slashes target to $4 from $18, maintaining a Buy rating. Dilution concerns overshadow diabetes and obesity programs. $LODE: Analysts slash outlook to $4 as dilution reigns supreme. More shares, less value… and the moon keeps moving further away. $CELC: Needham lowers target to $70 from $74, citing dilution concerns. Oncology dreams diluted by capital raises. $LULU: JPMorgan downgrades to Neutral with a $224 target, citing high valuation and slowing growth. Athleisure dreams on a treadmill.
0 · Reply
sirspanky
sirspanky Aug. 18 at 2:44 PM
$HCTI ⏳ countdown → Aug 28th = compliance milestone 🚨 After the Aug 1st split, the 20 trading day clock runs out on the 28th — that’s when the company can finally check the box on Nasdaq compliance ✅. 📊 Pair that with: Strong Q2 earnings turnaround 📈 Acquisitions bringing in contracts 💼 Institutional filings showing confidence 💪 28th becomes the perfect launchpad for management to start dropping PRs + updates to fuel momentum. This isn’t just another ticker — it’s a turnaround story aligning with compliance & catalysts. Tagging: $PLTR $BMEA
3 · Reply
Rob88ynn
Rob88ynn Aug. 17 at 4:22 PM
$BMEA https://www.ainvest.com/news/blue-owl-capital-holdings-lp-acquires-3-800-000-shares-biomea-fusion-strategic-investment-biotechnology-sector-2508/
0 · Reply
GODOFUSD
GODOFUSD Aug. 15 at 3:59 PM
$BMEA this stock will soon gap up into the moon
0 · Reply
NGEA
NGEA Aug. 15 at 10:43 AM
$BMEA According to 13F filed yesterday by BMEA, was BMEA silently buying back its shares, 3.83 million, from the open market or it was something I don't understand? can someone pls explain this to me? Thanks
1 · Reply
JohnRemy
JohnRemy Aug. 14 at 6:17 AM
$BMEA To clarify confusion of some people, options grants aren’t free money. They’re a normal part of executive pay in biotech. At $1.53 strike, they only have value if the company performs well enough to push the share price above that. If the pipeline fails, they’re worth zero. Unlike cash bonuses, options tie leadership’s payoff directly to shareholder gains. In a high-risk, high-burn biotech like BMEA, this is standard practice to keep key people on board through critical clinical milestones.
0 · Reply
avikiyan11
avikiyan11 Aug. 14 at 3:09 AM
$BMEA Both CEO and COO were gifted over 2.1 millions options to buy at $1.53 per share. No risk but a lot of reward for them.
2 · Reply
Jajjanajaqpapq
Jajjanajaqpapq Aug. 13 at 8:25 PM
$BMEA
1 · Reply
Jajjanajaqpapq
Jajjanajaqpapq Aug. 13 at 8:23 PM
$BMEA Michael Hitchcock (CEO of Biomea) just bought 1 million shares as well …..
3 · Reply
Jajjanajaqpapq
Jajjanajaqpapq Aug. 13 at 8:21 PM
$BMEA The founder and chief operating officer Ramses Ertdmann just bought 1.3 million shares. Shit is about to go down ( or in our case way up)
0 · Reply
GODOFUSD
GODOFUSD Aug. 13 at 4:42 PM
$BMEA institutionals FOMO
0 · Reply
raulsan79trader
raulsan79trader Aug. 13 at 2:12 PM
$ATNF $BMEA
0 · Reply
GODOFUSD
GODOFUSD Aug. 13 at 1:45 PM
$BMEA more calls, more shares, everyone want it
0 · Reply
Bullworks
Bullworks Aug. 12 at 7:35 PM
$BMEA
0 · Reply
GODOFUSD
GODOFUSD Aug. 12 at 5:35 PM
$BMEA
0 · Reply
GODOFUSD
GODOFUSD Aug. 12 at 4:55 PM
$BMEA
0 · Reply